巨噬细胞移动抑制因子
癌症研究
蛋白激酶B
癌变
MAPK/ERK通路
生物
肿瘤进展
PI3K/AKT/mTOR通路
细胞迁移
细胞因子
信号转导
细胞
医学
细胞生物学
免疫学
内科学
癌症
遗传学
作者
Ruimin Liu,Danni Sun,Ye-Lin Jiao,Pan Wang,Juan Zhang,Ming Wang,Jin Ma,Man Sun,Bianli Gu,Pan Chen,Ke Liu,Heng Ma,Shegan Gao,Yuanfang Ma,Yijun Qi
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2017-10-25
卷期号:412: 289-296
被引量:33
标识
DOI:10.1016/j.canlet.2017.10.018
摘要
The pleiotropic pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF), represents an important link between chronic inflammation and tumorigenesis. Although accumulating evidence demonstrates that MIF overexpression is implicated in the development and progression of multiple cancers, including esophageal squamous cell carcinoma (ESCC), the molecular mechanisms underlying its tumor-promoting roles in ESCC remain unclear. In the present study, we observed that MIF is overexpressed in ESCC and correlated significantly with lymph node metastasis, advanced clinical stage, and poor survival of ESCC. MIF knockdown attenuated the proliferation, migration, and invasion of ESCC cells in vitro and in vivo. Moreover, blockage of MIF expression decreased the activation of the Akt, MEK/ERK, and NF-κB pathways and enhanced sensitivity to apoptosis. Meanwhile, repression of MIF expression resulted in activation of glycogen synthase kinase 3 beta (GSK3β) and subsequent decrease of active β-catenin, as well as its downstream targets including cyclin D1, matrix metalloproteinase (MMP)-7, c-myc, and c-Jun. Collectively, our results provided mechanistic insights into the tumor-promoting role of MIF in ESCC, and suggested that MIF represents a potential therapeutic target for treatment of ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI